Study to Assess the Efficacy, Safety and Tolerability of Secukinumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)

A Multi-center, Open Label Study of Subcutaneous Secukinumab in Prefilled Syringes as Mono- or Co-therapy to Assess the Efficacy, Safety and Tolerability in Japanese Subjects With Generalized Pustular Psoriasis

The purpose of this study was to assess efficacy and safety data of secukinumab in Japanese subjects with generalized pustular psoriasis (GPP). This study was expected to support the filing of secukinumab in the indication of pustular psoriasis in Japan.

Inclusion Criteria:

• At baseline, presence of GPP classified on the basis of the criteria for diagnosis of GPP by Japanese Dermatological Association (JDA)
• At baseline, erythema area with pustule ≥ 10%

Exclusion Criteria:

• Erythrodermic, guttate psoriasis, or subcorneal pustular dermatosis at screening.
• At baseline, : total score of JDA severity index for GPP ≥ 14
• Drug-induced psoriasis
• Ongoing use of prohibited psoriasis treatments.